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Introduction
Rapid and reliable genetic screening method of 
human cancers is one of the interesting fields of 
research (Simi et al., 2008). There are several diagnostic 
methods for the investigation of cancerous mutational 
status of patients such as direct DNA sequencing and 
pyrosequencing (golden standard), TaqMan array, 
single-strand conformation analysis, allele-specific PCR 
(Dxs Therascreen), but they have some defects, including 
needing manipulation of amplified fragments or being 
labor intensive and time consuming(Tan et al., 2008; 
Wooster et al., 2006; Morandi et al., 2012; Packham et 
al., 2009; Sundstrom et al., 2010; Fransen et al., 2004). 
Sanger sequencing, is approved as a gold standard 
of sequence variation analysis and has high reliability 
but its disadvantages raised the applicability limitation 
as a diagnostic tool in routine laboratories and restricted 
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its functionality in research centers, respectively. One 
of its weak points is the use of several steps by distinct 
protocols (e.g. PCR, amplicon purification, labelling) 
that increased the contamination risks (Morandi et 
al., 2012; Packham et al., 2009; Krypuy et al., 2006). 
Given that, Sanger sequencing pitfalls such as being 
time-consuming, labor-intensive, and expensive or being 
in need of sophisticated devices introduce the suggestion 
of its gradual replacement by other sensitive, reliable, and 
efficient methods, (Morandi et al., 2012; Packham et al., 
2009; Krypuy et al., 2006).
High resolution melting (HRM) analysis is a high 
throughput emerging PCR-based method for rapid 
scanning of hereditary or somatic mutations with high 
accuracy (Simi et al., 2008; Krypuy et al., 2006; Negru 
et al., 2014). The screening of mutations by this method 
is based on the measurement of modifications in the 
melting profile of duplex, when the DNA is exposed 
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to an increasing temperature. These modifications 
monitored using the fluorescent dyes, which intercalate 
double-stranded fragments but no single-stranded 
fragments (Reed and Wittwer, 2004). Patterns of melting 
profile influenced by various variants, as a result wild type 
and homozygote-heterozygote sequences have different 
melting profile patterns (Boyd et al., 2011). 
KRAS and BRAF oncogenes are two genes of interest 
in cancerous cells’ investigation and their mutational status 
is important to patient’s cancer outcome. In this context, 
the sensitive and reliable methods compared and analyzed 
elsewhere (Borras et al., 2011). Common signaling 
pathways such as KRAS/BRAF/MEK/ERK activated in 
colorectal cancer (CRC) (Popovici et al., 2012; Vakil et 
al., 2016). Hydrolysis of guanosine triphosphate (GTP) 
molecules has a critical role in inactivation of complex 
KRAS genes produced by signal transduction protein 
(Pinto et al., 2011; Ji et al., 2007). Mutants of KRAS 
gene are less sensitive to hydrolysis and this leads to cell 
proliferation mediated KRAS (Ji et al., 2007; Koochak et 
al., 2016). In CRC patients, KRAS gene mutations were 
identified about 30-40% (Andreyev et al., 2001; Andreyev 
et al., 1998), which KRAS exon 2 mutations are more 
frequent (almost  90% at codons 12/13 in CRC patients) 
(Janakiraman et al., 2010; De Roock et al., 2011). KRAS 
activates the cytosolic protein kinase which encodes by 
BRAF gene (Roth et al., 2010). BRAF mutations induced 
cell propagation by MAPKs signaling cascade (Guedes et 
al., 2013; Allegra et al., 2009). BRAF mutation rates in 
CRC patients estimates approximately 10% and the most 
common substitution in BRAF gene is V600E in CRC 
patients (Minoo et al., 2007; Di Nicolantonio et al., 2008). 
Recently, before any specific therapy in CRC patients 
recommended the screening of KRAS and BRAF 
mutations as a necessity and due to the presence of 
some screening methods in this area, the reliable, rapid, 
and cost-effective diagnostic method is one of research 
interests. (Pinto et al., 2011). In the current study, our 
main objective was to validate the performance of HRM 
technique compared to allele specific PCR (DxS) and 
Pyrosequencing by samples (n=1000) that originated from 
colorectal cancer tissues for the detection of KRAS and 
BRAF mutations in selected subsets.  
Material and Methods
Participants
Samples were collected from Iranian mCRC patients 
who referred to Mehr Hospital, the main referral center 
for cancerous patients in Tehran, Iran from Feb. 2008 
to May 2012 and enrolled in this study. Written consent 
obtained from each patients and ethical committee of Iran 
University of Medical Sciences, Tehran, Iran approved 
ethics of present study. A total of 1,000 mCRC FFPE 
samples included 427 (42.7%) female by the average age 
of 55 years and 573 (57.3%) male by the average age of 
57 years were enrolled (Table 1). 
Formalin-fixed paraffin-embedded (FFPE) tissue DNA 
extraction
FFPE tissues were manually dissected by block 
trimming from 10 μm thickness collected in a microtube 
for genetic testing and digested by proteinase K at 56°C 
for 3 days in a rotating incubator. QIAamp® DNA 
FFPE Tissue Kit (QIAGEN, Hilden, Germany) used for 
genomic DNA extraction according to the manufacturer’s 
protocol. NanoDrop ND-1000® (Thermo Fisher Scientific 
Inc., Waltham, MA, USA) spectrophotometry used 
for concentration (ng/ul) and purity (OD 260/280nm) 
quantification of extracted DNA. Then, the extracted DNA 
was kept at -20°C before use. 
Pyrosequencing
The Qiagen PyroMark KRAS v.2.0 Q96 kit by specific 
primers used for the amplification of KRAS gene codons 
12 and 13. Master mix compounds of 12.5 μl PyroMark 
PCR Master Mix, 2.5 μl CoralLoad Concentrate, 1 μl 
PCR Primer KRAS 12/13, 4 μl Water (supplied) and 
5 μl sample DNA (2–10 ng concentration) in a total 
volume of 25 μl. PCR reactions performed on Veriti 96 
well Applied BioSystem thermal cycler by the heating 
program: initial denaturation at 95°C 15 min, 42 cycles 
of 95°C 20 s (denaturation), 53°C 30 s (annealing), 72°C 
20 s (extension) and one step of final extension at 72°C 
for 5 minutes.
The Qiagen PyroMark BRAF kit used for the detection 
of BRAF mutation according to the manufacturers 
instructions. Primers for BRAF codon 600 were obtained 
from the PyroMarkBraf v.2.0 kit. The PyroMark Q96 
software was used for sequence analysis.
PCR product confirmation of amplification by agarose 
gel (Sigma-Aldrich, St. Louis, USA) was recorded. Gel 
Band Purification Kit (GE Healthcare, Little Chalfont, 
UK) used for the purification of PCR products. Purified 
PCR products run on a PyroMark ID Pyrosequencing 
machine (QIAGEN, Germany) for sequencing reactions 
and PyroMark Q96 analysis software (QIAGEN, 
Germany) used for the analysis of electroperograms. All 
electropherograms were read manually. 
Dxs Therascreen 
Sequence variation of KRAS oncogene by six 
aminoacids (Gly > Ala, Asp, Arg, Cys, Ser and Val) 
on codon 12 and one (Gly > Asp) on codon 13 was 
investigated using TheraScreen DxS KRAS Mutation 
Kits KR-21 and KR-22 (QiaGen, Hilden, Germany) 
Demographic and pathological characteristics N %
Sex Male 573 57.3
Female 427 42.7
Age (y) ≤50 325 32.5
˃50 675 67.5
Tumor 
differentiation
Well Differentiated 439 43.9
Moderate Differentiated 384 38.4
Poor differentiated 164 16.4
Undifferentiated 13 1.3
Table 1. Demographic Characteristics of 1,000 mCRC 
Patients
Asian Pacific Journal of Cancer Prevention, Vol 17 5149
DOI:10.22034/APJCP.2016.17.12.5147
HRM Analysis for Screening of KRAS and BRAF Mutations 
rate of 4.4°C/s, amplification stage included 40 cycles of 
denaturation at 90°C 20 s by the ramp rate of 4.4°C/s, 
Annealing 67°C 20 s by the ramp rate of 2.2°C/s, and 
melting analysis at 72°C for 20 s by the ramp rate of 
4.4°C/s, 70°C for 1 s by the ramp rate of 4.4°C/s, 90°C 
continuous fluorescence data acquisition by the ramp 
rate of 0.02°C/s and 25 acquisitions per second, then 
cooling samples after HRM at 40°C 30 s by the ramp 
rate of 2.2°C/s.
Results
Mutational status of samples
A total of 1000 CRC samples were used for screening 
of KRAS and BRAF by HRM, Pyrosequencing and Dxs 
Therascreen methods. At first, HRM were performed for 
all of the subjects, the subsequent results were analyzed, 
and we have found that there were 33.6% (336/1,000) 
KRAS mutants and there were not any BRAF mutants. 
Among 336 KRAS mutants, 286 (85.1%) were codon 
12 mutant and 50 (14.9%) were codon 13 mutant (Table 
2). As shown in Figure 1, the most common mutation at 
KRAS codon 12 was Gly12Asp, then Gly12Val, Gly12Ser, 
Gly12Ala, Gly12Cys and Gly12Arg,. The positive KRAS 
mutant specimens did not contain any BRAF mutation. 
The Pyrosequencing as the golden standard and 
another Dxs Therascreen method were performed for 
checking and were compared with HRM results. However, 
the Pyrosequencing analyses the mutational status the 
same as HRM (Figure 2) and the Dxs Therascreen results 
confirmed them, as well. There were no differences in 
according to its recommended internal reaction control 
and a synthetic control template for the calculation of 
KRAS mutation degree differences. The LightCycler® 
Adapt Software v1.1 (Roche Diagnostics, Germany) was 
used for further analysis. Primers feature were included 
the 3´ end sequence-specific to mutation and Real-time 
PCR-Scorpion W primer tags.
TheraScreen K-RAS Mutation Kit version DU001PE 
used for PCR reactions by LightCyclerW480 II (Roche 
Applied Science, Penzberg, Germany) according to the 
instructions. Total reaction volume were 25 μl and thermal 
cycler protocol were included steps: initial denaturation at 
95°C in 4 min, 45 cycle at 95°C in 30 sec., (denaturation) 
and 60°C in 1 min (annealing). The fluorescence 
acquisition at the 60°C step (annealing) performed. Assay 
components included 19.8 μl reaction mix, 0.2 μl Taq, and 
5 μl of sample/control by a total volume of 25 μl in each 
reaction tubes. LightCycler Analysis Software 1.5.0 SP3 
program (Roche Applied Science, Penzberg, Germany) 
used for reports of the Ct and ΔCt values.
High resolution melting (HRM)
HRM method performed for the screening of KRAS 
mutation. LightCycler® 480 II Real-Time System 
(Roche Diagnostics, Basel, Switzerland) provided for 
PCR amplification and HRM. LightCycler® 480 Gene 
Scanning Software Version 1.5 (Roche diagnostics, 
Germany) used for data analysis.
PCR reaction performed by the following protocol: 
forward primer (GCC TGC TGA AAA TGA CTG AA) 1 
μl and reverse primer (TAT CGT CAA GGC ACT CTT 
GC) 1 μl, ddH2O 10 μl, genomic DNA (10 ng/μl) 3 μl, 
HRM master mix (QIAGEN) Mat. NO. 1057636 20 
µl in a final volume of 35 μl. Termocycler program for 
KRAS gene amplification were as follows: Initial PCR 
activation step (Pre-amplification) at 95°C for 5 min by 
ramp rate 4.4°C/s, amplification stage included 55 cycles 
of denaturation at 95°C for 10 s by ramp rate 4.4°C/s, 
annealing 63°C 30 s by ramp rate 2.2°C/s, and melting 
analysis at 63°C for 5 min by the ramp rate of 4.4°C/s, 
70°C for 1 s by the ramp rate of 4.4°C/s, 90°C continuous 
fluorescence data acquisition by the ramp rate of  0.02°C/s 
and 25 acquisitions per second, then cooling samples after 
HRM at 40°C 30 s by the ramp rate of 2.2°C/s.
For BRAF mutation detection initial PCR activation 
step (Pre-amplification) at 95°C for 10 min by the ramp 
Clinical and pathological characteristics KRAS wild type, KRAS mutant, N (%)
Total Codon 12 Codon 13
Sex Male 402 (60.5%) 171 (50.9%) 143 (83.6%) 28 (16.4%)
Female 262 (39.4%) 165 (49.1%) 143 (86.7%) 22 (13.3%)
Age (y) ≤50 235 (35.4%) 90   (26.8%) 74 (82.3%) 16 (17.7%)
˃50 429 (64.6%) 246 (73.2%) 212 (86.2%) 34 (13.8%)
Tumor Differentiation Well Differentiated 265 (39.9%) 173 (51.5%) 77 (44.5%) 96 (55.5%)
Moderate Differentiated 279 (42.0%) 108 (32.1%) 86 (79.6%) 22 (20.4%)
Poor differentiated 109 (16.4%) 54   (16.1%) 39 (72.2%) 15 (27.8%)
Undifferentiated 11   (1.7%) 1     (0.3%) 1 (100.0%) 0 (0.0%)
Total mCRC 1,000 patients 664 (66.4%) 336 (33.6%) 286 (85.1%) 50 (14.9%)
Table 2. Mutational Status of 1,000 mCRC Patients
Figure 1. Details of Detected Mutations of KRAS and 
BRAF
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detection of mutational status in KRAS gene in 33.6% 
of specimens in codon 12 or 13 and BRAF gene in none 
of them. 
Reliability and Sensitivity of HRM 
1,000 samples were screened to evaluate the reliability 
and sensitivity of HRM assay.  HRM results were 
compared with pyrosequencing and Dxs Therascreen 
method. Subsequently, the specificity and sensitivity of 
HRM were assessed as high in detection of 336 KRAS 
positive mutant samples and 664 wild types compared 
with two other methods. BRAF mutation was negative in 
all 242 KRAS mutant samples. Examples of HRM and 
melting profiles obtained from tissues carrying mutations 
of KRAS are shown in Figure 3. In all cases, the HRM 
is approved by the results of pyrosequencing and Dxs 
Therascreen. Consequently, the specificity and sensitivity 
of HRM analysis were 100% (Figure 4).
Discussion
Reliable and practicable screening of mutations 
in known genes would be requested in future clinical 
practice(Katsanis and Katsanis, 2013). Hence, there 
is noticeably an essential need for rapid and low-cost 
detection of mutations with high accuracy. Though 
DNA sequencing is recognized as the golden standard, 
it is less applicable in clinical screening of genes. This 
limitation can be explained by high costs and low 
sensitivity of sequencing (Krypuy et al., 2006). The main 
purpose of current study was to develop a sensitive test, 
which makes the rapid detection of hot-spot mutations 
of KRAS, and BRAF oncogenes possible in mCRC. 
HRM has been established for the detection of mutation 
from various samples, such as frozen tumor samples 
and archived specimens in the form of formalin fixed 
paraffin-embedded and methanol-fixed tissues (Chen et 
al., 2014). This method provides a reliable and inexpensive 
test to carry out mutational screenings of tumor specimens 
in the clinical practice and diagnostic lab (Li et al., 2012; 
Montgomery et al., 2010). A meta-analysis indicated 
that the overall values of the sensitivity and specificity 
of HRM were 0.99 (95% CI 5 0.75–0.82) and 0.99(95% 
CI 5 0.94–0.98), respectively (Chen et al., 2014). In our 
study, HRM confirms the results of pyrosequencing and 
Dxs Therascreen in all formalin fixed paraffin-embedded 
samples and these finding shown 100% sensitivity and 
specificity of HRM. The results obtained here suggest 
that the HRM, in comparison with DNA sequencing, is 
a more applicable technique for detection of the BRAF 
and KRAS mutations. It is also worth mentioning that one 
of the few disadvantages of HRM is that it cannot easily 
distinguish how many mutation are present, or where 
within the amplified fragment the mutation is positioned. 
For this, sequencing of the PCR product is essential 
(Chateigner-Boutin and Small, 2007).
Within several investigations, various factors had been 
testified that might affect the HRM accuracy, although the 
accuracy of HRM is remarkable (Wittwer, 2009). Takano 
et al. showed that sensitivity increased, when fresh tumor 
samples were used for HRM, a possible explanation for 
this event is degeneration of DNA throughout sampling, 
or the maintenance of the archived samples (Takano et 
al., 2007). Wittwer et al., (2009) reported that sensitivity 
and specificity of HRM for fragments smaller than 400 bp 
is 100% and they also indicated that sensitivity increased 
when melt profile contains just one or two melt domains 
not more. Another study showed that, when the amplicon 
lengths were between 400 and 1 kb, sensitivity and 
specificity decreased to 96.1% and 99.4%, respectively 
(Montgomery et al., 2010). It has been demonstrated that 
GC content fragments might affect the results of HRM 
and shown that lower GC content is associated with 
false negative results (Mader et al., 2008; Taylor, 2009). 
The finding of this study supports most of the previous 
investigation results regarding effectible factors on HRM 
sensitivity and specificity. Our samples almost were 
Figure 2. KRAS Analysis by Pyrosequencing. (Top 
Electropherogram) Wild Type (Normal) - (12Gly-GGT, 
13Gly-GGC), (Middle and Bottom Electropherogram) 
Mutant-KRAS (12Asp-GAT, 12Cys-TGT)
Figure 3. HRM Analysis Melting Profiles Obtained from 
Tissues Carrying Mutant KRAS
Figure 4. HRM Specificity and Sensitivity Diagram
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high GC content and short length but not fresh and were 
formalin fixed paraffin-embedded tissues. However, there 
again the maintenance conditions of archived samples in 
our lab was appropriate and not seems that DNA might 
have been degenerated. 
Collectively, current study verified the high sensitivity 
and specificity of HRM and our results seem to highlight 
the significance of HRM for precise scanning of KRAS 
mutations and BRAF screening. It is also possible to 
state that HRM may be a more attractive technique for 
the detection of known or unknown somatic mutations of 
other genes, in comparison with other methods. However, 
further research is required on this topic. In countries like 
Iran which costs of test affect the treatment, low cost of 
accurate HRM assay is the best choice. 
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